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Abstract
COST EFFECTIVENESS ANALYSIS IN ORTHOPAEDIC SURGERY.
Husham Sharifi and Mohammad Diab. Department of Orthopaedic Surgery, University of
California at San Francisco, San Francisco, CA. (Sponsored by Jonathan Grauer, Department of
Orthopaedic Surgery, Yale University School of Medicine.)

The purpose of this thesis was to explore the use of cost effectiveness for interventions in
orthopaedics. This was done through three cost effectiveness articles that have been published by
the author. In each of these articles, similar methodologies were used. Decision models were
constructed for cost-effectiveness analyses of competing orthopaedic interventions. Outcome
probabilities and effectiveness values were derived from the literature. Effectiveness was
expressed in quality adjusted life years gained. Cost data were compiled and verified from either
hospital cost data or from Medicare data. Costs and utilities were discounted in accord with the
United States Panel on Cost Effectiveness in Health and Medicine. Principal outcome measures
were average incremental costs, incremental effectiveness, incremental quality-adjusted life
years, and, in the case of one article, net health benefits. In particular the articles compared the
following: 1. Core decompression versus conservative management for osteonecrosis of the hip
as a way to delay hip replacement; 2. Total knee arthroplasty versus unicompartmental knee
arthroplasty; and 3. Periacetabular osteotomy versus total hip arthroplasty for a young adult with
developmental dysplasia of the hip. The more cost effective intervention was identified in each
case, along with implications of the results for clinical and operative decision-making. Cost
effectiveness was found to be a useful tool in orthopaedic surgery under limited circumstances of
either scarce data on new interventions or the need to use more resources to achieve greater
effectiveness. It also can provide excellent insight into ways to direct future clinical research.
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Introduction
The goal of clinical research is identify issues of concern to doctors and answer the questions that
those issues raise [1]. Randomized trials are the gold standard for providing these answers [2].
Unfortunately, randomized trials pose several inherent difficulties to structure, especially in
orthopaedic surgery. Most surgeries in orthopaedics have outcomes that are durable. They last for
years without any need for revision. A randomized trial would need to follow patients over an
extended span of time, which can be logistically complex. The problem becomes even more
challenging when one tracks a cohort large enough to achieve statistical significance. Even if
these challenges could be surmounted, they would not provide answers until long into the future.
Decisions still need to be made in the short and medium term. The expertise that comes from
experience can be used for interim decisions, and that expertise can be supplemented by decision
analysis.

The typical use of decision analysis in economic circles has been to assess competing alternatives
for achieving a common endpoint. Its use in orthopaedic surgery is to quantify variables for
patient outcome and apply these numbers to a model that adequately represents reality [3-5]. To
understand how this is the case, one must first have a clear definition of decision analysis.

Decision Analysis
The core idea of decision analysis is that resources are finite and that patient benefit must be
maximized given finite resources. This differs from regular clinical judgment in that the
information is quantified and the steps of the decision are put into a model. The model usually
takes the form of a decision tree, with the choice under consideration at the base of the tree. The
tree is built from left to right by adding successive branches. Each branch is made at a node, and
each node has an outcome. Outcomes are quantified in a way that represent value for the patient.
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In its simplest form a decision tree has only one decision to make, that of the first branch. In
orthopaedic surgery this usually means choosing one surgical technique over another. All
successive branches are constituted by chance nodes, in which each node is assigned a probability
of occurring based on the chance of a certain outcome. The chance may be determined by a
complication rate and a consequently mediocre outcome, by no complications and a consequently
excellent outcome, by needing a revision, by death, or in fact by any clinically relevant event.

In building such a tree the burden of approximating reality is on the modeler. The outcomes and
probabilities must come from the best possible evidence. When randomized trials are not
available, other sources may be suitable. Observational trials constitute such a source, as do
registries and claims databases. The latter may be especially useful with respect to cost
calculations. All these must be accessed through a systematic review of the literature. Systematic
review may already have been done in a database such as the Cochrane database, or it may need
to be done by the modeler. Inclusion and exclusion criteria should be determined beforehand and
should be transparent to anyone looking at the model. The goal of the literature review is to find
clinically relevant outcomes and probabilities. Although a decision tree is formed before the onset
of reviewing the literature, it should be continuously revised to reflect clinical reality as closely as
possible. The literature review itself can help iterate and improve the tree.

Just as the exclusion/inclusion criteria should be transparent, the results of the literature review
should be transparent. In fact they should comprise part of the reported methodology. In the ideal
case the modeler would present a meta-analysis in which effect size is calculated according to a
meta-regression. Study characteristics would be statistically controlled when calculating overall
averages. In reality most decision analysis studies will compile simple means. There will also be
cases in which the literature does not provide adequate results. This may be especially true for
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quantified measurements of health outcomes. In such a case one may need to rely on expert
opinion (i.e., the opinion of an experienced doctor involved in the modeling effort).

The quantification of health outcomes is in fact one of the more difficult tasks in developing a
decision analysis. One may try to achieve objectivity by measuring an outcome as the absence of
a well-known complication. In cardiology, for example, this could be the measurement of
whether ventricular remodeling occurs after a myocardial infarction. The administration of an
ACE inhibitor reduces the probability of such a complication. The percentage of patients who do
not have ventricular remodeling would be the outcome. There are many limitations to such an
approach, a discussion of which is outside the scope of this thesis.

The trend among researchers in the field of decision analysis is to include outcomes that represent
the value experienced either by the patient directly or by society at large. To be specific, an extra
year of life in a vigorous state of health may have a higher value for a patient than an extra year
spent undergoing chemotherapy. That year may also be valued differently by society, which loses
the benefit of an individual’s contributions and, in some form, incurs the cost of treatment.
Conventional opinion is that the best way to capture these differences is in the form of quality
adjusted life years (QALYs) [6-8]. Numerically, QALYs are defined as the extra years of life
achieved by the patient multiplied by a utility that represents the quality of living during those
years. The utility is measured on a scale of 0 to 1, with 0 being death and 1 being the highest
possible quality of life. In most cases these utilities are obtained from the patients themselves,
using measurement techniques such as time tradeoff and standard gamble [6]. In a minority of
cases, utilities are determined by a proxy for the patient, such as the doctor [9, 10]. There are
questionnaires that assess utility, such as EuroQoL and the Short Forms. Additionally, there are
new methods that translate Short Form 36 and Short Form 12 into utilities that range from 0 to 1
[11].
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The next step is to cull the literature for probability rates of possible outcomes. The process for
doing so is described above, and often the effort of finding appropriate outcomes leads one to
discover corresponding probabilities and complications. This activity helps to fill in and further
develop the decision tree. Once all of these data are established and appropriately modeled, one
can run the tree. It can be run as a Markov model, if the states under consideration are best
represented as iterations over an extended period of time. Alternatively, it can be run as a static
decision tree, in which final outcomes – that is, outcomes at the far right of the tree – are
multiplied by the probability of the branch that leads to them. These are then represented on the
node that gives rise to the branch. The process is continued with probabilities and branches that
precede each node. It is repeated until the single decision at the left-most side of the tree is
reached. That yields a utility of one decision versus another, which in orthopaedics means one
procedure versus another.

Such a static model is of course restrictive. Even with the most careful literature review and the
most conscientious model development, one still does not capture even a small fraction of clinical
reality. Sensitivity analysis offers enough flexibility to address this problem. Input for the model
is varied along clinically relevant ranges, which is defined both from the literature and from
expert opinion of doctors in the field. When limited evidence supports a particular variable, the
range for the sensitivity analysis should be broad. When an abundance of evidence exists, the
range can be narrow. In all cases the robustness of variables is assessed. Robustness determines
how much a result depends on a specific variable. A result depends greatly on the value of a
sensitive variable; it depends very little on the value of a robust variable. Put differently, a small
change in a sensitive variable produces a large change in the final result. A large change in a
robust variable produces a small change in the final result. Such an understanding of the model
comes from one-way, univariate sensitivity analysis – that is, changing one variable at a time and
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seeing what the consequent model outcome is. Whenever possible, one should also perform
multivariate sensitivity analysis in which 2 or more variables are changed simultaneously and
consequent model outcome is assessed. Even for weak models, this activity allows doctors to use
results in a way that is much more likely to reflect the reality they face from day to day.

The entire process that has been described is in fact not cost effectiveness analysis. (See
Appendix A for the distinction between cost effectiveness and cost utility.) It does not include
cost. The inclusion of cost may appear simple at face value; in reality it poses tremendous
challenges. First, one must decide whether they use readily available charge data, such as is
published in Medicare diagnostic related groups (DRGs). These rarely reflect the actual
expenditure to the care provider, and the difference can be either an underestimate or an
overestimate. More accurate estimations often require permission to review hospital financial data
and are more difficult to access. Fortunately, the accounting software of the hospital’s financial
department does an adequate job of assessing the resources used by an institution for a given
procedure.

The other challenge is the perspective from which cost is calculated. The cost incurred by the
individual is different than the cost incurred by the health care system. Premium-based insurance
plans in fact create incentives for direct conflict between these two. Furthermore, the cost
incurred by society is a third cost altogether. One way to grapple with the issue is to separate
direct costs and indirect costs. Direct costs includes goods, services, and other resources that were
consumed in the provision of care. Indirect costs include issues such as opportunity costs, which
measure what cost an individual incurs when losing one opportunity in order to benefit from
another opportunity. For example, a woman who misses several days of work to undergo a
procedure benefits from the procedure but loses some amount of wage earnings. Another example
of an indirect cost is when a spouse must spend time taking care of a patient in the post-operative
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period instead of participating in other activities. In essence indirect costs capture the idea of cost
from the perspective of society. For this reason they are favored by practitioners of cost
effectiveness.

The assessment of indirect costs can be daunting. There is admittedly no satisfying solution, as of
the writing of this thesis, to the challenge. It appears to be a common problem in the world of
modeling outside of medicine as well, which suggests that it may be inherent to the methodology
of decision analysis. Some physicians suggest that the calculations produced by hospital
accounting software serve as adequate proxies for cost from a societal perspective, which
includes indirect costs [6, 7].

The final step in the inclusion of cost is to ensure that monetary values accurately reflect the
value of money in the present day. In the world of finance, there is enough liquidity and
transparency in currency exchange that we can roughly assess the value of a currency with
respect to goods and other currencies. This results in historical records of the changing value of
money, which in the US has been a rate of inflation of 2-5% for the last 25 years. When data on
outcomes are gathered, they must be discounted by a percentage rate that takes into account the
real devaluation of our currency. The model can then use cost data expressed in current dollar
values. The same requirement applies to projections into the future. Convention dictates that both
costs and utilities should be discounted at approximately 5% [6, 7].

Decision analysis in orthopaedic surgery
Orthopaedic surgery as a field can benefit from decision analysis as it is described above. The
following 3 articles illustrate the use of cost effectiveness analysis, with the application of the
principles that have been laid out. These articles are the product of research conducted and
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published by the author of this thesis. The first article analyzes the cost effectiveness of core
decompression of a hip with osteonecrosis as a way to delay hip replacement. The second article
analyzes the cost effectiveness of total knee arthroplasty versus unicompartmental knee
arthroplasty. The third article analyzes the cost effectiveness of periacetabular osteotomy versus
total hip arthroplasty in the treatment of the young adult with developmental dysplasia of the hip.
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Methods
Cost-effectiveness Analysis of Core Decompression
General Framing and Design
This cost-effectiveness analysis follows the methodological guidelines of the Panel on Cost
effectiveness in Health and Medicine convened by the US Public Health Service in 1993[6]. The
panel outlined an explicit set of recommendations in a reference case analysis. These reference
case guidelines established a common set of standards to improve the comparability of costeffectiveness analyses. Issues addressed in the reference case analysis include standard practices
for framing and perspective of the study, identification of outcomes, estimation of costs, and
testing of uncertainty [6]. This study was constructed adhering to these standards.

Consistent with the reference case guidelines, this analysis compares the cost-effectiveness of
core decompression to the commonly accepted treatment alternative of observation in the early
stages of osteonecrosis. This analysis assumes a target patient population seeking treatment of
femoral osteonecrosis at the age of 40 years. The time horizon of this analysis encompasses the
remaining life expectancy for this target population.

The cost effectiveness ratios for observation and core decompression were analyzed from the
societal perspective. The boundary of the analysis is limited to the costs and health effects
directly impacting the target population. Estimates of costs, effectiveness, and the probability of
various outcomes were obtained from literature review.

Literature Review
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Literature review was used to construct the event pathways following observation and core
decompression. A literature search identified 269 articles between 1978 and 2004 using the
keywords osteonecrosis, decompression, hip, and outcome. Seventy- eight articles were identified
as relevant to the treatment of osteonecrosis with either core decompression or observation.
Fifteen publications were review articles and excluded from further analysis. The remaining
articles were assessed on their quality. We excluded articles with fewer than 50 subjects.
Additional criteria used to select articles included adequate reporting of magnetic resonance
imaging staging and standardized surgical technique. A total of 11 studies were identified and
selected for abstraction using these criteria. A summary of the abstracted data are included in
Appendix B.

Decision Model
Decision tree software (TreeAge Pro; TreeAge Software Inc, Williamston, Mass) was used to
create a model for the treatment of femoral head osteonecrosis [8, 12-17]. A simplified schematic
of the decision tree is shown in Figure 1. The model begins with the decision for either
observation or core decompression. Literature review was used to identify possible outcomes and
their probability after each of these treatment alternatives. These event pathways were
incorporated as branches in the decision tree. This model assumed a target population of patients
seeking treatment of osteonecrosis at the age of 40 years. This age is consistent with the typical
age at which core decompression is performed for osteonecrosis of the hip [18]. The time horizon
of the model follows events through the remaining life expectancy of 39 years for this age group
[19]. The event pathway for observation follows the clinical course of patients with early
osteonecrosis and assumes that they become symptomatic and require THA after a 2-year period.
This period is consistent with the natural history of osteonecrosis [18, 20, 21].
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QuickTime™ and a
TIFF (Uncompressed) decompressor
are needed to see this picture.

Figure 1: Simplified schematic of decision model for the treatment of femoral head osteonecrosis

The event pathways following core decompression were constructed following literature review.
There has been a wide range of results reported on the efficacy of core decompression [22-30]. A
reference case was created and assumed a period of 10 years before the need for primary hip
arthroplasty after core decompression compared with 2 years with observation. This assumption
is consistent with the more favorable reports of the results of core decompression. The efficacy of
core decompression in delaying hip arthroplasty for this duration has not been definitively
established in the published literature. Given this uncertainty, the effects on the cost-effectiveness
of core decompression of both shorter and longer assumptions for its efficacy are examined in the
sensitivity analysis. The primary complication included in the model following core
decompression is subtrochanteric hip fracture requiring operative intervention. This complication
has been infrequently reported, but rates as high as 5% have been published [22-30]. An
intermediate value of 2% was selected for the reference case, and sensitivity analysis was used to
examine the effect of rates in the range of 0% to 5%.

Subsequent events after observation and core decompression are modeled to include the potential
need for hip arthroplasty and revisions over the lifetimes of the target population. Complications
after hip arthroplasty include dislocation, infection, and death [31]. The decision model
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incorporates the need for subsequent hip revision surgery and the possible complications that can
arise. The incidence of complications is assumed to increase with subsequent revision procedures,
whereas the durability of revision arthroplasty is assumed to decrease relative to primary
arthroplasty [32-34]. The probabilities of infection, dislocation, and mortality used in this model
are shown in Table 1. The rates of these complications were selected to fall in the midrange of
estimates reported in the literature. Most studies have reported rates of infection leading to
implant failure near the value of 1% used in the reference case of this study [32, 33, 35, 36].
Mortality and dislocation rates have not been as definitively established. The reference case of
0.5% for mortality is consistent with the low rates generally reported [37]. The dislocation rate of
2.5% used in the reference case is consistent with reports of large database studies [31, 33].
Sensitivity analysis was used to address the uncertainty of these assumptions for complication
rates by examining the effect of higher and lower rates on the results.

Complication

Probability (%)

Complication rate primary THA

4

Infection

1

Dislocation

2.5

Mortality

0.5

Complication rate revision THA

10

Complication rate second or third revision THA

15

Table 1: Complication Rates Used in Decision Model After THA

Effectiveness
This study is a special case of cost-effectiveness analysis termed cost-utility analysis. Cost-utility
analyses are differentiated by the fact that effectiveness is measured in units that incorporate a
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subjective measure of utility such as quality adjusted life years (QALYs). The treatment of
osteonecrosis has limited effect on survival but does result in significant changes in the quality of
life of patients. The use of QALYs to measure effectiveness allows the survival of patients in
different health states to be corrected for health related quality of life using a utility factor.

Utility factors were assigned to all health states in the model to adjust survival for quality of life.
The reference case guidelines define utility along a continuum with a factor of 1.0 representing
perfect health and a factor of 0.0 representing death [6] . Specific utility values for each health
state in this study were assigned following a literature review. Table 2 lists the health states
included in the decision model along with their corresponding utility values. Large-scale studies
have used questionnaires to establish utility values for a variety of health states. Arthritis has
consistently been shown to have a utility value near 0.7 [11, 38-40]. Knee and hip arthroplasties
have been shown to increase quality of life weightings close to normal values. Based on these
studies, this analysis uses a utility value of 0.9 for successful hip arthroplasty. Revision
arthroplasty is given a lower utility value to reflect the diminished clinical results compared with
primary arthroplasty. The utility values used for resection arthroplasty and surgical complications
were also identified in literature review.

Health state

Utility value

Primary THA

0.9

Treatment of dislocation

0.5

Treatment of infection

0.5

Surgery and postoperative recovery

0.5

Death

0.0

Successful core decompression

0.9
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Revision THA

0.85

Resection hip arthroplasty

0.6

Table 2: Utility Values for Health States Occurring in Decision Model

The period after successful core decompression was assigned a utility similar to that of successful
arthroplasty. This reflects the assumption that successful core decompression results in a wellfunctioning hip but does not completely restore normal utility. The ability of core decompression
to control symptoms and maintain a high level of function has not been definitively documented
in the published literature. To address this uncertainty, sensitivity analysis was used to examine
the impact of both higher and lower utility values after core decompression on its costeffectiveness.

Costs
Gross-costing methodology was used to estimate the direct lifetime treatment costs after both
observation and core decompression [6]. This methodology relies on global Medicare charge and
reimbursement data to approximate the direct costs for various procedures. Indirect costs such as
lost productivity were not included in this analysis. The surgical interventions occurring in the
decision model were assigned their appropriate International Classification of Diseases, Ninth
Revision; diagnosis related groups (DRGs); and Current Procedural Terminology (CPT) codes.
Gross cost estimates were then determined for short-term care hospitalizations and physician
services based on charge and reimbursement data for these codes. The cost estimates are shown in
Table 3.
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Procedure

DRG (cost [$])

Core decompression

210 (8086)

Primary THA

209 (9183)

Revision THA

209 (9183)

Resection arthroplasty

210 (8086)

Reduction of dislocated hip prosthesis

210 (8086)

Operative treatment of infected hip prosthesis

210 (8086)

Open reduction and internal fixation of hip fracture

210 (8086)

Table 3: Costs for DRG and CPT Codes Occurring in Decision Model Using 1998 Medicare
Data

Gross cost estimates for short-term care hospitalizations were determined from mean hospital
costs for the DRG associated with each intervention. Mean hospital costs were based on data
from the Centers for Medicare and Medicaid Services reported for 1998 [41]. These costs are
derived by applying Medicare cost-to-charge ratios to the data from the MedPAR data source
[41]. The MedPAR data source is released annually by Medicare and provides cost estimates for
each DRG. This study used the MedPAR data for 1998 pertaining to all US hospitals [41, 42].

The gross costs for physician services were determined from mean Medicare reimbursement for
the CPT code associated with each surgical intervention. The mean reimbursement reported by
the Centers for Medicare and Medicaid Services in 1998 for the Los Angeles, California, carrier
was used. This global reimbursement includes preoperative care, surgical fees, and 90 days of
postoperative care [43].
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Discounting
Cost-effectiveness analysis requires that all future costs and health consequences be discounted
and stated in their present-day values. Discounting is performed to correct for the fact that costs
that are deferred to the future are preferable to immediate expenditures. Costs and health effects
were discounted in the reference case at a constant rate of 3% annually. Sensitivity analyses were
conducted with discount rates of 0% and 5% [6, 8].

Sensitivity Analysis
Sensitivity analysis was conducted to test the uncertainty of the reference case results. Cost
effectiveness analysis combines information from several data sources to generate estimates of
the probability of different outcomes and assign values to their utility and costs. Uncertainty
about the true values of these underlying parameters results in uncertainty about the costeffectiveness ratios generated in the reference case. Sensitivity analysis is used to determine the
impact of varying the assumed values for key variables on the conclusions generated by the costeffectiveness analysis.

Initially, cost effectiveness ratios were calculated using the reference case assumptions for both
observation and core decompression. Sensitivity analysis was then performed using different
assumptions for the values of the underlying variables [6]. Several key variables were selected for
sensitivity analysis. These variables included the delay in hip arthroplasty resulting from core
decompression, the functional utility after successful core decompression, the incidence of
complications after core decompression, and the incidence of complications after both primary
and revision hip arthroplasty.

20

Cost-Effectiveness Analysis of Unicompartmental Knee
Arthroplasty as an Alternative to Total Knee Arthroplasty for
Unicompartmental Osteoarthritis
This cost-effectiveness analysis follows the methodological guidelines of the Panel on CostEffectiveness in Health and Medicine convened by the United States Public Health Service in
1993[6]. Consistent with these reference case guidelines, the present analysis compares the costeffectiveness of unicompartmental arthroplasty with the commonly accepted treatment alternative
of total knee arthroplasty for unicompartmental arthritis. This analysis assumes a target patient
population seeking treatment for unicompartmental arthritis at the age of sixty-five years. The
time horizon of this analysis encompasses the remaining eighteen years of life expectancy for this
target population [19]. The cost effectiveness ratios for unicompartmental and total knee
arthroplasty were analyzed from the societal perspective. The boundary of the analysis is limited
to the costs and health effects directly impacting the target population. Estimates of costs,
effectiveness, and the probability of various outcomes were obtained from a literature review.

Literature Review
A literature review was used to construct the event pathways following initial treatment with
unicompartmental knee arthroplasty and total knee arthroplasty. We identified 345 articles,
published from 1975 through 2004, using the following keywords: unicompartmental,
unicondylar, knee arthroplasty, results, outcomes, cost, and effectiveness. We included articles
published in the years 1994 through 2004 in order to best reflect the results from the current
clinical use of unicompartmental knee arthroplasty. We excluded studies involving fewer than
fifty subjects. Additional criteria used to select articles included the selection of patients with an
intact anterior cruciate ligament and documented unicompartmental disease and the exclusion of
patients who had a prior patellectomy or tibial osteotomy. A total of nine studies were identified
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and selected for abstraction with use of these criteria [44-52].

Decision Model
Decision-tree software (TreeAge Pro; TreeAge Software, Williamstown, Massachusetts) was
used to create a model for the treatment of unicompartmental arthritis [8, 12-17]. A simplified
schematic of the decision tree is shown in Figure 2. The model begins with the decision for either
unicompartmental or total knee arthroplasty. A literature review was used to identify possible
outcomes and their probability following each of these treatment alternatives.

QuickTime™ and a
TIFF (Uncompressed) decompressor
are needed to see this picture.

Figure 2: Simplified schematic of the decision model for the treatment of unicompartmental
arthritis of the knee. TKA = total knee arthroplasty, and UKA = unicompartmental knee
arthroplasty.

The event pathways following unicompartmental knee arthroplasty and total knee arthroplasty
were constructed following the literature review. A wide range of results has been reported on the
effectiveness of unicompartmental knee arthroplasty [44-53]. The reference case assumes a
period of twelve years for the durability of a unicompartmental arthroplasty. This assumption is
consistent with results of unicompartmental knee arthroplasty in the nine studies selected for data
abstraction [44-52]. Sensitivity analysis was used to examine the effects on the cost-effectiveness
of unicompartmental knee arthroplasty of both shorter and longer assumptions for its durability.
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Total knee replacement was assumed in the reference case to have a survival of fifteen years. This
value is longer than the survival assumed for unicompartmental knee replacement and reflects the
fact that long-term outcomes have been more thoroughly documented for total knee replacement
[54].

Subsequent events following unicompartmental knee arthroplasty and total knee arthroplasty
were modeled to include the potential need for revision total knee arthroplasty as well as
complications over the lifetime of the target population. Complications included infection and
death[54]. The rates of these complications were selected to fall in the midrange of estimates
reported in the literature. Most studies have described rates of infection leading to implant failure
near the value of 1% used in the reference case of this study [54-56]. The reference case of 0.5%
for mortality is consistent with the low rates generally reported [56].

Effectiveness
Utility factors were assigned to all health states in the model to adjust survival for quality of life.
The reference case guidelines define utility along a continuum with a factor of 1.0 representing
perfect health and a factor of 0.0 representing death [38]. Specific utility values for each health
state in this study were assigned following a literature review (Table 4). Arthritis has been shown
to have a utility value near 0.723 [38]. Knee and hip arthroplasty have been shown to increase
quality-of-life weightings close to normal values. On the basis of these studies, this analysis uses
a utility value of 0.9 for successful unicompartmental and total knee arthroplasty [11, 38-40].
Revision arthroplasty is given a lower utility value to reflect the diminished clinical results
compared with primary arthroplasty. Previously published data were used to assign a utility value
of 0.6 for resection arthroplasty and 0.5 to periods of surgery and postoperative recovery
following complications [40]. Sensitivity analysis was used to examine the effect of uncertainty
about the utility values for unicompartmental knee arthroplasty and total knee arthroplasty on the
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cost-effectiveness results.

Health State

Utility Value

Primary total knee arthroplasty

0.9

Unicompartmental knee arthroplasty

0.9

Treatment of infection

0.5

Surgery and postoperative recovery

0.5

Death

0.0

Revision total knee arthroplasty

0.85

Resection knee arthroplasty

0.6

Table 4: Utility Values for Health States Occurring in the Reference Case of the Decision Model

Costs
Gross-costing methodology was used to estimate the direct lifetime treatment costs following
both unicompartmental and total knee arthroplasty [6]. The surgical interventions occurring in the
decision model were assigned their appropriate ICD-9 (International Classification of Diseases–
Ninth Revision), DRG (Diagnosis-Related Group), and CPT (Current Procedural Terminology)
codes. Gross-cost estimates for acute care hospitalizations were determined from mean hospital
costs for the DRG associated with each intervention. The mean hospital costs were based on data
from the Centers for Medicare and Medicaid Services reported for 1998 [57]. These costs are
derived by applying Medicare cost-to-charge ratios to the data from the Medicare Provider
Analysis and Review File (MEDPAR) data source [57]. The MEDPAR data source is released
annually by Medicare and provides cost estimates for each DRG [42, 57]. The gross costs for
physician services were determined from the mean Medicare reimbursement for the CPT code
associated with each surgical intervention (Table 5) [43].
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DRG

CPT

Procedure

Code

Cost

Code

Cost

Unicompartmental knee arthroplasty

209

$9183

27446

$1445

Primary total knee arthroplasty

209

$9183

27447

$1951

Revision total knee arthroplasty

209

$9183

27487

$2298

Resection arthroplasty

210

$8086

27488

$1348

210

$8086

27310

$797

Operative treatment of infection around knee prosthesis

Table 5: Costs for DRG and CPT Codes in Decision Model with Use of 1998 Medicare data.
Values are based on 1998 United States dollars. DRG = Diagnosis-Related Group, and CPT =
Current Procedural Terminology.

Discounting
Cost-effectiveness analysis requires that all future costs and health consequences be discounted
and stated in terms of their present-day values. Discounting is performed to correct for the fact
that costs that are deferred to the future are preferable to immediate expenditures. Costs and
health effects were discounted in the reference case at a constant rate of 3% annually [6, 8].

Sensitivity Analysis
Sensitivity analysis was used to determine the impact of varying the assumed values for key
variables on the conclusions generated by this cost-effectiveness analysis. Cost effectiveness
analysis combines information from several data sources in order to generate estimates of the
probability of different outcomes and to assign values to their utility and costs. Uncertainty about
the true values of these underlying parameters results in uncertainty about the cost-effectiveness
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ratios generated in the reference case. Sensitivity analysis was performed with use of different
assumptions for the values of the underlying variables [6]. Several key variables that were
selected for sensitivity analysis included the durability of unicompartmental knee replacements
relative to total knee replacements, the functional utility following unicompartmental
arthroplasty, and the cost of unicompartmental knee arthroplasty.

Cost-Effectiveness Analysis of Periacetabular Osteotomy
General Model Overview
The model and analysis in this study were constructed according to the guidelines set forth by the
Panel on Cost- Effectiveness in Health and Medicine by the United States Public Health Service
in 1993 [6, 7, 58].

We compared the cost-effectiveness of periacetabular osteotomy and total hip arthroplasty in
young adults with developmental dysplasia of the hip. The upper age limit of our population was
forty-five years, and the time horizon of the model was thirty years. The cost-effectiveness for the
two procedures is reported from a societal perspective, which accounts for costs and outcomes
that are important for society rather than for the payer, the physician, or any other single entity
[59]. Effectiveness and outcome probabilities were obtained from the literature or estimated when
data were lacking.

The analysis was performed through a decision tree by using a common decision-analysis
package (TreeAge Pro 2005; TreeAge Software, Williamstown, Massachusetts). An essential
component of this model was the assumption of a linear annual failure rate for periacetabular
osteotomy and total hip arthroplasty. A systematic review of the literature and expert opinion
were used to validate the decision tree [9, 60-71]. We searched PubMed through September 2006
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for articles using the terms ‘‘periacetabular osteotomy’’ and ‘‘total hip arthroplasty.’’ Inclusion
criteria were a sample size of greater than twenty-five hips, follow-up of longer than three years,
mean patient age of forty-five years or less, quantitative outcomes reported as Harris hip scores,
and outcomes reported by Tonnis grade for periacetabular osteotomy. All data points for total hip
arthroplasty, except for cost, were taken from the literature. Where data were not available for
periacetabular osteotomy, we took the most conservative estimate based on the expert opinion of
two senior orthopaedic surgeons. The model included only objective outcomes. Pain, although
not directly assessed, was taken into account by use of the Harris hip score. Because several
periacetabular osteotomy studies have shown a correlation between postoperative success and the
preoperative radiographic grade of coxarthrosis [65, 70, 72, 73], we ran the model once for each
Tonnis grade, measuring costs and outcomes for each run. Total hip arthroplasty outcome was the
same regardless of preoperative radiographic coxarthrosis grade [66].

Decision Model
Our decision tree (Fig. 3) consists of two primary treatment arms: periacetabular osteotomy and
total hip arthroplasty. Branching points thereafter represent complications and terminate in
outcomes. Outcomes were assigned a quantitative health-related quality of-life value derived
from the literature. Clinical outcome probabilities, including complications and failure rates, were
derived from the literature. The total hip arthroplasty arm of the model is similar to past models
of arthroplasty [9, 74, 75]. The weight of each variable was explored by means of multivariate
sensitivity analysis.
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QuickTi me™ and a
decompressor
are needed to see this picture.

Figure 3: Main decision tree. PAO = periacetabular osteotomy; THA = total hip arthroplasty;
DDH = developmental dysplasia of the hip; OA = osteoarthritis; HO = heterotopic ossification

Table 6 summarizes the sensitive variables used in the model. Sensitive variables yield
quantitatively large effects on model outcome and are hence addressed in detail herein. In
contrast, robust variables are those that, as determined by sensitivity analysis, do not significantly
affect model outcome. Probability inputs for the model were annual probabilities derived by
dividing the overall failure rate by the average follow-up time reported in the literature, thereby
yielding a linear failure rate. For total hip arthroplasty, the complications modeled were aseptic
and septic failure. Our model represents quality of life after a successful revision total hip
arthroplasty as being slightly lower than quality of life after a successful primary total hip
arthroplasty [76, 77]. Similar to a previously validated total hip arthroplasty model, aseptic failure
included prosthetic wear, loosening, and breakage [9]. The literature reports an annual aseptic
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failure rate in the range of 1.9% to 3.7% [74, 78-83]. We selected a weighted average of the
above studies at an annual aseptic failure rate of 2.6%.

Variable

Value

Probability of Primary Aseptic Failure

.026 per annum

Average Lifespan of THA

14 years

Average Lifespan of PAO

10 years

Utility of an Excellent Outcome

1.0

Table 6: Sensitive variables used in the model. Sensitive variables have a significant effect on
model outcome.

For periacetabular osteotomy, the complications modeled were periacetabular osteotomy failure
resulting in conversion to total hip arthroplasty, periacetabular osteotomy revision secondary to
overcorrection or undercorrection, and heterotopic ossification. Failure rates of periacetabular
osteotomy were modeled to be different according to Tonnis grade, with rates of 1%, 3%, and 9%
for Tonnis grades 1, 2, and 3, respectively [70]. The probability of revision was modeled to be
4% [68], and the probability of heterotopic ossification was 2.4% [70]. Other possible
complications, such as neural or vascular injury, were so rare [63] and transient that they exerted
no effect on cost and effectiveness and were thus excluded from the model.

The longevity of total hip arthroplasty varies with respect to the population in which the
procedure is performed. When it was possible, we used total hip arthroplasty studies that
described results in an age group similar to that in which periacetabular osteotomy is a treatment
option. By extracting data from articles that directly report a mean or median survival of total hip
arthroplasty [80, 82, 84], and by confirming those values by extrapolating median survival
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through an assumption of a linear failure rate, we found that survival of total hip arthroplasty
ranges from 6.6 to 25.9 years [74, 78-82]. The value we chose to use, fourteen years, is the
weighted average of the above trials.

Because of the lack of longer-term follow-up with periacetabular osteotomy, the longevity of the
procedure is still unknown. In order to determine a survival range for sensitivity analysis, we
extrapolated the median survival of periacetabular osteotomy by assuming a linear failure rate in
articles describing follow-up for periacetabular osteotomy beyond four years. The resulting range
of values for median survival was 8.6 to 19.6 years, while the weighted mean survival was ten
years [60, 68, 70, 72, 73, 85, 86]. For the best and worst-case scenarios, we used empirical data
derived from studies describing the survivability of periacetabular osteotomy in hips with more
than four years of follow-up [71, 72, 85], ranging from 7.1 years in one study [85] to twelve years
(twenty-two of twenty-six hips) in another [73]. The value chosen for our reference case was ten
years, and it was based on the weighted mean survival reported above.

Medical Costs
Cost data (not charge data) were compiled and verified with use of our institution’s activity-based
costing software (IDX, Burlington, Vermont) that tracked our hospital decision support system.
Cost data are reported in 2004 U.S. real dollars. The range of values was determined by
identifying the lowest and highest costs in our patient cohort. Costs for heterotopic ossification
were estimated, and the impact of estimating that cost was assessed in the sensitivity analysis.
When we varied the cost of heterotopic ossification from $5000 to $15,000, it changed the
breakeven points by less than one month, which is negligible over the multiple year time horizon
of our model. Thus, estimating the cost of heterotopic ossification was not deemed important.
Costs were discounted at a rate of 5% in order to yield the present monetary value. The time of
failure of a hip impacted cost— hips that failed earlier incurred potentially more cost in the time
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course of the model.

Utilities
We determined effectiveness in terms of health-related quality of life, which was ascertained by
applying the continuous utility assessment method devised by Hazen et al. [10] and applied to
total hip arthroplasty by Chang et al. [9]. We mapped health-related quality of- life values to
Harris hip scores according to the system of Chang et al., and patient utility analyses done before
and after total hip arthroplasty [56, 67, 87]. Consistent with the outcomes reported in the
literature, a successful primary periacetabular osteotomy in hips with Tonnis grade-1, 2, and 3
coxarthrosis had health-related quality-of-life values of 1.0, 0.8, and 0.6, respectively [70]. The
same health-related quality-of-life value was given to either total hip arthroplasty or
periacetabular osteotomy, according to the outcome assessed by Harris hip scores, and a
corresponding adjectival rating was given. In our final analysis, utility values were multiplied by
the discounted number of years spent in a health state to yield quality adjusted life years
(QALYs) gained. QALYs were discounted at a rate of 5% to yield present value [6, 8, 12]. As
with cost, the time of failure of a hip impacted the outcome patients with a hip that failed earlier
potentially may live longer with a lower health related quality of life. A successful total hip
arthroplasty subsequent to failure of a periacetabular osteotomy was assigned a good healthrelated quality-of-life outcome of 0.8 rather than the excellent outcome of 1.0, associated with a
primary total hip arthroplasty.

Incremental cost-effectiveness ratios were used to aid comparison of treatments. The incremental
cost-effectiveness ratio presented in the results is averaged over the thirty-year time horizon of
the model. The incremental cost-effectiveness ratio is calculated as follows: (CostPAO –
CostTHA) / (QALYsPAO – QALYsTHA), with PAO indicating periacetabular osteotomy and
THA indicating total hip arthroplasty. The net health benefit was used as a measure of outcome
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from a societal perspective because it takes into account the willingness of the health-care system
to pay (WTP). The net health benefit may be calculated as QALYs – Cost /WTP [88]. The net
health benefit, while not usually reported in the orthopaedic literature, is used in other specialties
as it offers the advantage of easy comparison between different treatment strategies. When two
cost-saving treatments are compared, the better modality has the higher net health benefit,
whereas it would have the lower incremental cost-effectiveness ratios since incremental costeffectiveness ratios can be expressed in negative terms [88-91].

Sensitivity Analysis
Sensitivity analysis addressed the uncertainty inherent to drawing data from multiple sources [6].
In the case of our model, variables that made a substantial contribution to results were deemed to
be sensitive, whereas those that contributed <1% to the total outcome were deemed robust. We
varied sensitive variables according to coxarthrosis, measured radiographically as grade 1, 2, or 3
according to the method of Tonnis [92].

An expanded sensitivity analysis was conducted on the average duration of Tonnis-grade 1 and
grade-2 hips after periacetabular osteotomy on the basis of a best-case and a worst case scenario
for survival. For these two end-point scenarios, we chose the lowest and highest average survival
rates reported in the literature for periacetabular osteotomy [73, 85]. We did not do this for
Tonnis grade-3 hips because changing the value of hip survival does not change the results
substantially.
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Results
Cost-effectiveness Analysis of Core Decompression
Reference Case Results
A reference case was created that assumed that core decompression delays the need for THA for
10 years. Given the uncertainty of this assumption, the effects on the cost-effectiveness of core
decompression of both shorter and longer assumptions for its efficacy are examined in the
sensitivity analysis.

In the reference case, the pathway of core decompression is assumed to delay hip arthroplasty for
10 years and resulted in 20.20 QALYs, whereas observation resulted in 19.75 QALYs. This
represents an incremental gain of 0.45 QALYs when core decompression was chosen over
observation. Core decompression generated total expected lifetime treatment costs of $27498.
This results in an incremental increase in cost of $4298 when compared with the lifetime
treatment costs of $23200 for observation followed by arthroplasty. This led to an incremental
cost-effectiveness ratio of $9551 for each QALY gained when core decompression was chosen
over observation.

Sensitivity Analysis
Effect of Changing the Assumed Length of the Delay in the Need for THA After Core
Decompression.
The reference case assumes that core decompression delays hip arthroplasty for 10 years as
compared with 2 years with observation in the early stages of osteonecrosis. Core decompression
has not been definitively demonstrated to result in delays of this length. There are conflicting
reports in the literature, with some authors showing delays of this length and others reporting
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results below this threshold [18, 93]. Sensitivity analysis was used to evaluate the effects of
varying the underlying assumption for the success of core decompression on its cost effectiveness
ratio. The cost effectiveness of core decompression decreases as its assumed ability to delay hip
arthroplasty decreases. The cost effectiveness ratio rises to more than $25000 per life year as the
period of delay falls below 7 years. The $50000 cost per life year gained threshold is passed as
this period falls below 5 years.

Effect of Function After Core Decompression.
The reference case assumes that successful core decompression prevents painful symptoms
during the period it is delaying the need for primary arthroplasty. This control of pain is reflected
in the high utility value of 0.9 assigned to patients during this waiting period. Sensitivity analysis
was conducted to model clinical situations in which core decompression does not perform well in
mitigating the functional limitations caused by advancing osteonecrosis. The cost-effectiveness
ratio of core decompression rises to more than $50000 per QALY gained when the utility during
the period after the procedure and before conversion to THA is assumed to be lower than 0.86.

Effect of Complication Rate After Core Decompression.
Subtrochanteric hip fractures complicating core decompression have been reported infrequently,
although some studies have shown rates as high as 5%. Sensitivity analysis demonstrated that the
cost-effectiveness ratio rose or fell only slightly over the range of values from 0% to 5%. Even at
an assumed fracture rate of 5%, the cost-effectiveness ratio of core decompression remained
lower than $12000 per QALY.

Effect of Complication Rates After Arthroplasty.
The rates of complications after THA have been reported by several authors [31, 33-37]. The
assumed durability of hip arthroplasty and incidence of complications including death,
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dislocation, and infection were selected to be in the midrange of accepted values. Sensitivity
analysis was used to examine the impact of using high- and low-range values for these variables.
As the assumed complication rates after hip arthroplasty decrease, core decompression becomes a
less cost-effective treatment option. This occurs because some of the cost-effectiveness gains
from core decompression result from the delay or avoidance of the costs and negative health
impacts that result from these complications. However, these effects were not large and did not
alter the conclusions of this study. Even under conditions in which the complication rates of THA
are assumed to be negligible, core decompression remained highly cost-effective with an
incremental cost effectiveness ratio lower than $13000 per QALY gained.

Effect of Discount Rate.
Analyses assuming discount rates of 0% and 5% in addition to the baseline assumption of 3%
were conducted. These variations in the discount rate did not have a large impact on the costeffectiveness ratios. A discount rate of 0% led to an incremental cost effectiveness ratio for core
decompression of $12429 per QALY gained. A discount rate of 5% resulted in a ratio of $9620
per QALY gained. These ratios fall well below the threshold of $50000 per QALY commonly
used to judge procedures as moderately cost-effective [6].

Cost-Effectiveness Analysis of Unicompartmental Knee
Arthroplasty as an Alternative to Total Knee Arthroplasty for
Unicompartmental Osteoarthritis
Reference Case Results
A reference case was created with use of the assumption that unicompartmental arthroplasty
results in a high level of function for twelve years. The assumption of twelve years of function is
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consistent with that in published clinical series, but there are limited data available that directly
compare the durability of unicompartmental knee replacement and total knee replacement [4453]. Given the uncertainty of this assumption, the impact on the cost-effectiveness of
unicompartmental arthroplasty of both shorter and longer assumptions for its effectiveness is
examined in the sensitivity analysis.

In the reference case, the pathway of unicompartmental knee arthroplasty resulted in a small gain
in effectiveness to 12.21 quality-adjusted life years compared with 12.19 quality adjusted life
years when total knee arthroplasty is chosen. There was minimal change in costs, with an increase
from $18,995 to $19,000 (in 1998 United States dollars). The incremental cost-effectiveness ratio
for unicompartmental knee arthroplasty under the reference case assumption is negligible with a
cost of $277 per quality-adjusted life year gained. This ratio indicates that unicompartmental knee
arthroplasty was more effective than total knee arthroplasty, and this increased effectiveness
required a minimal additional cost.

Sensitivity Analysis
Effect of the Durability of Unicompartmental Knee Replacement Compared with Total Knee
Replacement
The durability of unicompartmental knee replacements remains uncertain relative to total knee
replacements. Sensitivity analysis was used to evaluate the effects of this uncertainty by varying
the underlying assumption for the durability of unicompartmental knee replacements and
determining the changes to the cost-effectiveness ratio. The cost effectiveness of
unicompartmental knee arthroplasty is lost as the durability of the implant is assumed to decrease.
The reference case assumes a survival of fifteen years for primary total knee replacement. The
assumption of a longer survival for total knee replacement compared with unicompartmental knee
replacement reflects the longer experience and more complete documentation of the durability of
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total knee replacement. The cost-effectiveness of unicompartmental knee arthroplasty relies
largely on its ability to produce clinical results approaching those of total knee arthroplasty. In
sensitivity analyses that assume unicompartmental knee replacement has a survival of eleven
years, it becomes both less effective (12.16 compared with 12.19 quality-adjusted life years) and
more costly than standard total knee arthroplasty ($19,233 compared with $18,995). This scenario
results in total knee arthroplasty becoming a dominant choice. Specifically, total knee
arthroplasty becomes both more effective and less costly when unicompartmental knee
replacement is assumed to have a survival below the threshold of eleven years (Table 7).

Values Used in Sensitivity Analysis

Incremental Cost of
Unicompartmental
Compared with Total
Knee Arthroplasty

Incremental Effectiveness
of Unicompartmental
Compared with Total Knee
Arthroplasty (QALY)

Reference case
Unicompartmental knee
replacement survival assumed to
be 12 yr.
Total knee replacement survival
assumed to be 15 yr.
Scenario 1
Unicompartmental knee
replacement survival assumed to
be 11 yr.
Total knee replacement survival
assumed to be 15 yr.
Scenario 2
Unicompartmental knee
replacement survival assumed to
be 17 yr.
Total knee replacement survival
assumed to be 20 yr.
Scenario 3
Unicompartmental knee
replacement survival assumed to
be 15 yr.
Total knee replacement survival
assumed to be 20 yr.
Cost of unicompartmental knee
arthroplasty increased by 25%
Cost of unicompartmental knee
arthroplasty decreased by 25%

+$5

+0.02

Incremental CostEffectiveness Ratio of
Unicompartmental Compared
with Total Knee Arthroplasty
(Cost/QALY)
$277

+$238

0.03

TKA is dominant

+$6,236

+0.13

$45,958

+$6,859

+0.05

$117,103

+$2,661

+0.02

$165,354

-$2,652

+0.02

Unicompartmental knee
replacement is dominant
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Table 7: Incremental Costs, Effectiveness, and Cost-Effectiveness Ratios with Use of Reference
Case and Sensitivity Analyses

Multivariate sensitivity analysis was also performed with use of a broader range of fifteen to
twenty years for the expected durability of total knee replacement. These analyses indicated that
it is necessary for the assumed survival of the unicompartmental knee replacement to be within
three to four years of the assumed survival of the total knee replacement in order to maintain the
cost-effectiveness of choosing unicompartmental knee arthroplasty. This is demonstrated by
analyses that assume that total knee replacement survival is twenty years. With use of this
assumption, the incremental cost-effectiveness ratio of unicompartmental knee arthroplasty is
$45,958 per quality-adjusted life-year gained compared with total knee arthroplasty when a
unicompartmental knee replacement is assumed to survive for seventeen years. This is below the
commonly accepted threshold of $50,000 per quality-adjusted life year often used to determine
cost effective procedures [6, 9]. In contrast, when the survival of a unicompartmental knee
replacement is assumed to be fifteen years and the survival of a total knee replacement is assumed
to be twenty years, the incremental cost-effectiveness ratio increases to more than $100,000 per
quality-adjusted life-year gained (Table 7). The incremental cost effectiveness ratio continues to
increase, and the cost-effectiveness of unicompartmental knee arthroplasty decreases as the
survival of a unicompartmental knee replacement is assumed to be lower relative to the survival
of a total knee replacement.

Effect of Function Following Unicompartmental Knee Arthroplasty
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The initial published findings indicate that unicompartmental knee arthroplasty results in function
that is at least comparable with that seen after total knee arthroplasty [44, 46-52, 94]. The
reference case reflects these results by assuming that both unicompartmental knee arthroplasty
and total knee arthroplasty result in a high level of function and pain relief. However, there are a
limited number of controlled studies that have directly compared the clinical function after
unicompartmental knee arthroplasty and total knee arthroplasty. This uncertainty was addressed
in a sensitivity analysis that examined the effect of higher and lower values for the utility of
unicompartmental knee arthroplasty on its cost effectiveness.

The reference case results show a small gain of 0.02 quality-adjusted life years when
unicompartmental knee arthroplasty is chosen over total knee arthroplasty. These gains are lost
when the utility of unicompartmental knee arthroplasty is assumed to be less than that of total
knee arthroplasty. Conversely, there is a further incremental increase in the cost-effectiveness
when the utility of unicompartmental knee arthroplasty is assumed to be >0.9. When
unicompartmental knee arthroplasty is assigned the maximal value of 1.0, it results in a total of
13.20 quality-adjusted life years as opposed to 12.19 quality-adjusted life years for a gain of 1.01
quality-adjusted life years. Unicompartmental knee arthroplasty becomes a more cost-effective
choice under these assumptions, as the gains in incremental effectiveness increase with no
additional cost relative to the reference case.

Effect of Cost of Unicompartmental Knee Arthroplasty
There is a small incremental additional cost from unicompartmental knee arthroplasty with use of
the reference case assumptions for the relative costs of unicompartmental and total knee
arthroplasty. The minimal cost increase in the reference case results from the assumption that
there is a decrease in the physician’s fee for unicompartmental knee arthroplasty relative to the
fee reimbursement for total knee arthroplasty. Unicompartmental knee arthroplasty becomes a
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less cost-effective alternative in a sensitivity analysis in which the cost of unicompartmental knee
arthroplasty is assumed to be higher than the cost of total knee arthroplasty. An increase of 25%
resulted in an incremental cost-effectiveness ratio of $165,354 per quality adjusted life year
gained when unicompartmental knee arthroplasty was chosen over total knee arthroplasty. This
indicates that the cost-effectiveness of unicompartmental knee arthroplasty may be lost if it
requires a large relative increase in cost compared with total knee arthroplasty (Table 7 above).

The use of gross costing based on Medicare reimbursement does not account for the potential
savings of unicompartmental knee arthroplasty from implant costs or decreased hospital length of
stay. This is due to the fact that both unicompartmental knee arthroplasty and primary total knee
arthroplasty are assigned the same DRG, resulting in a similar cost assumption for the hospital
stay. A sensitivity analysis was performed to examine the effect of a 25% cost-savings in a
comparison of unicompartmental knee arthroplasty with total knee arthroplasty. A decrease of
25% in the assumed costs of unicompartmental knee arthroplasty resulted in an overall savings of
$2652 in the lifetime treatment costs compared with those of primary total knee arthroplasty
(Table 7 above).

Cost-Effectiveness Analysis of Periacetabular Osteotomy
Cost
Costs were averaged over the thirty-year time horizon of the model. The average cost of total hip
arthroplasty in all three Tonnis grades of coxarthrosis was $32,790. In Tonnis grade-1 and grade2 hips, periacetabular osteotomy yielded a cost of $26,592 and $30,673, respectively. The cost of
periacetabular osteotomy in Tonnis grades 1 and 2 was cost-saving compared with total hip
arthroplasty, i.e., it was below the abscissa in Figure 4. Periacetabular osteotomy in Tonnis grade
3 was associated with a cost of $33,465, which resulted in an incremental cost (above the abscissa
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in Figure 4) of $675.
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Figure 4. Average incremental costs and incremental quality-adjusted life years for periacetabular osteotomy (PAO) compared with total hip arthroplasty (THA).

Effectiveness
QALYs gained were averaged over the thirty-year time horizon of the model. In each of the three
Tonnis grades of coxarthrosis, total hip arthroplasty resulted in an average of 4.7QALYs gained.
Periacetabular osteotomy in Tonnis grade-1, 2, and 3 hips yielded an average of 4.85, 3.3, and 3.2
QALYs gained, respectively. Compared with the QALYs gained with total hip arthroplasty, the
increment in QALYs gained with periacetabular osteotomy in Tonnis grade-1 coxarthrosis was
0.15 (represented in Figure 4 by the data point for Tonnis grade-1 hips lying to the right of the
ordinate). In addition, for Tonnis grade-2 and grade-3 hips, total hip arthroplasty yielded, on the
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average, more QALYs (both data points lie to the left of the ordinate) than did periacetabular
osteotomy (Fig. 4).While over thirty years, total hip arthroplasty is more effective (i.e., it yields
more QALYs) on the average than periacetabular osteotomy in Tonnis grade-2 coxarthrosis,
periacetabular osteotomy becomes the more effective treatment by year 19.4 of the model. For
Tonnis grade-3 coxarthrosis, total hip arthroplasty is and remains more effective throughout the
time period of the model.

Cost-Effectiveness and Incremental Cost-Effectiveness
Cost-effectiveness ratios were averaged over the thirty-year time horizon of our model. The costeffectiveness ratio of total hip arthroplasty was $11,631/QALY for all three Tonnis grades. In
Tonnis grade-1, 2, and 3 coxarthrosis, periacetabular osteotomy had a cost-effectiveness ratio of
$7856/QALY, $10,807/ QALY, and $15,005/QALY, respectively. Since periacetabular
osteotomy in Tonnis grade-1 coxarthrosis is, on the average, both more effective than total hip
arthroplasty and more cost-saving (lower right quadrant in Figure 4), it is the dominant procedure
in this setting. For Tonnis grade-1 coxarthrosis, periacetabular osteotomy is more cost-effective
over thirty years and surpasses total hip arthroplasty in cost-effectiveness at 5.5 years. In Tonnis
grade-2 coxarthrosis, periacetabular osteotomy is less costly than total hip arthroplasty on the
average but also less effective (lower left quadrant in Figure 4). While both incremental cost and
effectiveness are negative for periacetabular osteotomy in Tonnis grade-2 coxarthrosis, the former
effect is greater than the latter effect, making periacetabular osteotomy ultimately more costeffective than total hip arthroplasty in this grade, with an associated incremental costeffectiveness ratio of –$824/QALY. For Tonnis grade-2 coxarthrosis, periacetabular osteotomy is
more cost-effective over thirty years and surpasses total hip arthroplasty in cost-effectiveness at
18.25 years. Periacetabular osteotomy was both more costly and less effective on the average than
total hip arthroplasty in Tonnis grade-3 coxarthrosis (upper left quadrant in Figure 4); as a result,
total hip arthroplasty is the dominant procedure in this setting.
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Net Health Benefits
Figures 5 and 6 depict the results for the two treatments in terms of net health benefits. In Tonnis
grade-1 coxarthrosis (Fig. 5), periacetabular osteotomy yields a greater net health benefit after
10.1 years in comparison with total hip arthroplasty. In Tonnis grade-2 coxarthrosis (Fig. 6),
periacetabular osteotomy reaches equivalence by 19.1 years, after which it becomes dominant. If
periacetabular osteotomy can be expected to have a greater longevity than the crossover points of
10.1 years and 19.1 years for Tonnis grade 1 and 2, respectively, then periacetabular osteotomy as
a treatment would be preferable to total hip arthroplasty in terms of net health benefits. Finally, at
no point does periacetabular osteotomy yield a negative net health benefit in both Tonnis grades 1
and 2, whereas total hip arthroplasty does so at 23.5 years and 25.1 years, respectively. These
results are summarized in Table 8, which shows how long (in years) a periacetabular osteotomy
must survive to become the preferred treatment modality.
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Figure 5. Tönnis 1 Incremental Net Health Benefits $/QALY's (WTP = $50,000).
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Figure 6. Tonnis 2 Incremental Net Health Benefits $/QALY's (WTP = $50,000).

Survival of PAO

Tönnis

needed to be

grade 1

preferred

Tönnis

treatment (years)

grade 2

Effectiveness

Cost

Cost Effectiveness

NHB

10.8

PAO always

5.5

10.1

18.25

19.1

THA always preferred

THA always

preferred
19.4

PAO always
preferred

Tönnis

THA always

THA always

grade 3

preferred

preferred

preferred

Table 8. The number of years PAO needs to survive for it to be a preferred treatment over THA,
given assessment by either Effectiveness, Cost, Cost-Effectiveness or NHB (Net Health Benefits).

Sensitivity Analysis
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We performed a multivariate sensitivity analysis for each Tonnis grade. Multivariate analysis
identified five consistently sensitive variables for Tonnis grades 1 and 2 that contributed >99% of
the total variability in outcome: (1) average lifespan of the periacetabular osteotomy, (2)
probability of a failed periacetabular osteotomy, (3) average lifespan of a total hip arthroplasty,
(4) probability of an aseptic revision, and (5) utility of excellent outcome.

We summarize the results of our worst and best-case analyses in Table 9. The cost-effectiveness
and effectiveness of periacetabular osteotomy improved considerably as the functional life of the
Tonnis grade-1 hip after periacetabular osteotomy increased. In the worst-case scenario,
periacetabular osteotomy is, on the average, more cost-effective than total hip arthroplasty and
reaches equivalence at 11.45 years for Tonnis grade-1 coxarthrosis. In the worst-case scenario for
Tonnis grade-2 coxarthrosis, periacetabular osteotomy, while it is not more cost-effective, on the
average, than total hip arthroplasty, reaches equivalence at 18.6 years. The range of reaching
equivalence is broader from best-case to worst-case scenarios for Tonnis grade-1 compared with
Tonnis grade-2 coxarthrosis because periacetabular osteotomy survival is not as sensitive a
variable for the latter. For both Tonnis grade-1 and grade-2 hips, periacetabular osteotomy always
remained below $50,000 per QALY gained for all of the values we tested in our sensitivity
analysis.

Tönnis grade 1

Worst case

Tönnis grade 2

Avg CE ($/QALY) :

Avg E (QALYs) :

Avg CE ($/QALY) :

Avg E (QALYs) : EV

EV time (years)

EV time (years)

EV time (years)

time (years)

- 5689 : 11.45

-1.1 : 16.35

200 : 18.6

-1.9 : 19.8

-7856 : 5.5

.15 : 10.8

- 824: 18.25

- 1.4 : 19.4

scenario
Reference
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case
Best case

- 8800 : 2.45

1.0 : 5.9

- 1152 : 17.8

-1.1 : 19.2

scenario

Table 9. Sensitivity analysis based on worst case and best case durability of a PAO hip showing
average incremental cost-effectiveness (Avg CE), average incremental effectiveness (Avg E), the
time point where equivalence between PAO and THA is attained (EV time) in terms of costeffectiveness and effectiveness, and the peak effectiveness of PAO in terms of maximum potential
gain in QALYs over the time span of our model.
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Discussion
With each passing year, healthcare costs consume an ever increasing percentage of our Gross
Domestic Product (GDP) [95]. Disease burden in the US is no greater than in peer countries of
the Organization for Economic Co-operation and Development (OECD), but our input costs are
intrinsically more expensive [96]. Unfortunately, we are getting a bad deal for this high price, at
least by the metrics we claim to be important. Within the group of OECD countries, the US has
among the highest infant mortality rates, the lowest life expectancies, and the greatest level of
obesity [97]. We pay a premium cost for an inferior result.

One possible reason for this combination is our reimbursement structure. Before 1982, the
government reimbursed physicians according to the cost of a procedure. Resource intensive
procedures predictably acquired favor. Diagnostic related groups (DRGs) were instituted to
address the perverse incentive of trying to use more resources in order to increase
reimbursements. The new incentive created by DRGs, however, was to spend less time per
procedure in order to perform as many procedures as possible. We still do not know with precise
statistics how this dynamic has affected outcomes in medical practice.

Most recently, there have been attempts to link reimbursement to outcome metrics, such as
quality or efficiency [98]. There are several potential requirements to make a value-based
reimbursement structure that focuses first and foremost on patient welfare while still accounting
for resource constraints. Two of the most prominent requirements are unambiguous measures of
quality and accurate measurements of cost. Within the realm of orthopaedic surgery, this thesis
presented 3 articles that compared quality and cost for alternative treatments.

Defining costs
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Costs can be direct or indirect, as was discussed in the introduction. In terms of cost effectiveness
analysis, this is usually where researchers end their measurements. That is a mistake.
Considerations of other types of cost are crucial, in particular fixed cost, variable cost, average
total cost, and marginal cost.

Fixed cost is defined as a cost that does not vary with usage. The cost of an operating room table
is an example. The hospital buys the table and installs it. The cost of doing so remains the same
no matter how many times it is used. Fixed costs can change over the long term, however,
especially if the product depreciates. The operating table may require, for example, more
maintenance as it gets older. A subset of fixed costs that cannot change over the long term is sunk
costs. These costs occur when an item with a fixed cost cannot be used for any other purpose in
the short term or long term. An old operating table might be used for instructional purposes in
another setting, but the operating suite itself has only one purpose. The former is a regular fixed
cost; the latter is a sunk cost.

Variable costs change according to the amount of output being produced. The salaries of scrub
nurses paid on a per time basis are examples of variable costs, as they increase with both longer
surgeries and with the number of surgeries performed. The amount of gloves and towels used for
a surgery constitute another example. Total costs equal fixed costs plus variable costs.

Average total cost is simply the total cost divided by the quantity produced. Marginal costs are
the cost of producing one extra unit. Marginal cost differs from average total cost when the
production of an extra unit raises or lowers the variable cost. In the corporate world the difference
between the two is obvious. When workers in a car factory make their first car, they become more
proficient at their job. Production of their second car is therefore done more rapidly and with
fewer mistakes (i.e., variable cost goes down). Production of their third car improves as well,
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although data show that the rate of improvement decreases – that is, there is a negative second
derivative that represents diminishing returns. This means that marginal cost is less with each
subsequent car, up to a certain plateau.

Perhaps the same applies to the learning curve of a surgeon for a new procedure. The state of
surgery research, however, is that none of this has been studied. From an economics perspective,
we do not have good data on marginal costs in the healthcare environment. This is acceptable
when deciding whether to apply a new intervention to a population that is receiving no
intervention at all. In that case average total costs can be used. It is a problem in cases such as the
articles in this thesis, in which one compares a newer procedure to a more established procedure.
Marginal cost is a more sensible approach for comparing competing procedures [99, 100].

Interpreting results
The driving reason for doing a cost effectiveness analysis is ambiguity. If a newer intervention
were both more effective and less costly, it would be adopted without hesitation – indeed, without
analysis. Analysis is necessary for two reasons: 1. Cases in which the effectiveness and cost of
the newer intervention are not known with accuracy; and 2. Cases in which the newer
intervention is superior in just one category, typically in being more effective, but inferior in the
other category, typically in being more costly.

For the first reason, cost effectiveness analysis is done to give a range of values that a doctor can
use in his practice. This was the case for the knee arthroplasty article in this thesis. The costs of
the procedures were not easily available to the researchers, especially the indirect costs as usually
represented in hospital accounting software. We were compelled to use DRG charge data and
validate these data with costs from the literature. Additionally, the outcome of the newer
procedure, the unicompartmental knee arthroplasty, was not known with any statistical power.
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We therefore conducted a sensitivity analysis with several scenarios to explore how long the
unicompartmental knee arthroplasty would need to last before revision in order to be as cost
effective as a total knee arthroplasty. The take-home message for an orthopaedic surgeon is that a
UKA does not need to last as long as a TKA to be as cost effective. It could last 3 - 4 years less,
and this difference held whether the duration of the TKA were 20 years, 15 years, or some value
in between. The experienced orthopaedic surgeon could assess how long his total knees last and
prognosticate accordingly.

The PAO article illustrates both cases. There is an ambiguity about the effectiveness of PAO, and
PAO may be superior in only one category, cost or effectiveness. Data on the outcomes of PAO
are scarce. This was one of the motivations for conducting research on it. We wanted to
understand, at a minimum, how long a PAO must last in order for it to be a worthwhile procedure
compared to THA. The answer to this question happened to differ according to Tonnis grade. For
it to be worthwhile just in terms of effectiveness in Tonnis grade 1, it needed to last 10.8 years.
For it to be worthwhile just in terms of effectiveness in Tonnis grade 2, it needed to last 19.4
years. In Tonnis grade 3 it was never more effective, and when cost was factored in, these
numbers changed. PAO was found to be less costly in Tonnis grades 1 and 2 and more costly in
Tonnis grade 3. For example, when factoring in cost and effectiveness for Tonnis grade 1, a PAO
needed to last only 5.5 years to be the preferred choice. In Tonnis grade 2 it needed to last 18.25
years to be preferred.

By reporting the results in this manner, we gave the orthopaedic surgeon the option to use them as
he wishes. If money were no object, it would mean that the surgeon would use only the duration
thresholds for effectiveness. In resource-limited environments, by contrast, the duration threshold
for cost-effectiveness could be considered.
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This approach also demonstrates the situation in which PAO may be better in only certain
settings. Specifically, PAO was found to be much less costly on average in Tonnis grade 1. It was
also found to be slightly more effective. If one believes that these assertions are well founded, the
decision to use PAO is automatic. In this setting PAO is the dominant choice. Similarly, in
Tonnis grade 3 PAO is both more costly and less effective. If one believes that these particular
assertions are well founded, one must conclude that THA in this setting is dominant. Beyond the
usefulness of quantifying these issues and analyzing them in a transparent structure, cost
effectiveness analysis is a worthy exercise in the middle scenario. For PAO, this was Tonnis
grade 2, where PAO is less costly than THA but on average is also less effective. This grey zone
is where the orthopaedic surgeon will seek out data to make a judgment. In the absence of data, a
model such as ours can be used, which is precisely what was represented in Figure 4 in the results
section for PAO.

Limitations of cost effectiveness
Perhaps one of the greatest limitations of this kind of research comes from the state of research in
orthopaedic surgery. There is such a shortage of well-conducted, large randomized trials in
orthopaedics that the data sources for the models are limited. Even the most well constructed
model has little value when its inputs are of low quality. The gold standard for assessing clinical
benefits is the randomized controlled trial. In the case of many orthopaedic procedures, and
certainly in the case of the ones assessed in this thesis, this is not easily feasible. Such trials
would take years to complete and would have prohibitive costs. By the time they were completed,
the technology of the field would have evolved to a new stage.

Large registries are an acceptable alternative, such as the nationwide hip registry in Sweden.
Indeed, much of my THA data comes from that registry. Whether or not such a registry is

52
possible in a country without a national healthcare system, such as the US, is still an open
question.

Another problem with assessing cost and effectiveness in medicine in general is that the best way
to do so would be to integrate these factors into the very methodology of every prospective
clinical trial. Tracking resource use and assessing outcomes should in fact be done simultaneously
in order to understand specific links between which resources lead to which outcomes.
Unfortunately, the data points required to achieve statistical significance for economics variables
are much greater than those needed for clinical variables. The addition of economic analysis to a
clinical trial is therefore highly likely to make the trial underpowered [100, 101].

Given this situation, we face a problem of “garbage in, garbage out.” The only time the issue can
be avoided is when the older technology has an established abundance of data, such as with THA.
In that case we can use sensitivity analysis on the newer technology to assess when and how it
can be useful. As pointed out, this approach was used in the analysis of PAO and THA.

There is also a concern with the methodology of cost effectiveness analysis. QALYs are by
definition subjective measurements of value. They depend on individual preferences, translated
into utilities, and these individual preferences are then applied to the general public. There may
be huge variations for any given patient on how they value an extra year of life with, for example,
the ability to walk free of pain [102, 103]. Furthermore, differences in these preferences may vary
dramatically across cultures as well as within professions that have greater physical demands
[104]. There is also the considerable ethical problem that QALYs by definition will be less for
older patients with fewer remaining years of life and for patients with co-morbidities that
guarantee a lower baseline utility. All of these issues highlight that cost effectiveness is a relative
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measure. It should be used to enhance clinical judgment with the comparative thresholds and
benchmarks it can produce. Absolute statements of cost effectiveness are not useful.

Cost effectiveness analysis can also be used to advance the state of research. Models allow us to
estimate, for example, an adequate population size needed to conduct a randomized trial. They
would also inform us how much time would be required for completion. These models can help
identify which variables (i.e., duration of the implant, complication rates, patient characteristics)
are most influential in determining the total cost effectiveness of the procedure. A doctor can then
pay particular attention to these in the decision process. A researcher can use these to target
fruitful areas of inquiry [105], and in fact the model itself may prove simply that no conclusions
can be drawn until more powerful data are gathered on sensitive variables. Finally, cost
effectiveness helps us determine whether the information in the literature is specific enough. If in
fact it is too general, then it serves as a warning to the researcher or surgeon that patients should
be subdivided depending on characteristics. For PAO versus THA, for example, this could mean
subdivision of THA into several categories of implants, such as ceramic on ceramic, metal on
metal, and ultra-high molecular weight polyethylene.
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Appendix A – Definition of Cost Utility Analysis
Each article contained the term cost effectiveness in it, but this term is a misnomer. A cost
effectiveness analysis, in the strict sense, measures health outcomes in units that are specific to
the two procedures under comparison. For example, a fractured femur could potentially be fixed
by external fixation or by internal fixation. One common outcome shared by these two methods is
the rate of nonunion. The cost of each procedure would be compared with nonunion rates in a
cost effectiveness analysis. In essence a cost effectiveness analysis uses an outcome that is
deemed important by the doctor.

By contrast, a cost utility analysis uses units that are standardized to all potential procedures, and
the unit of outcome takes into account the preferences of the patient. The current consensus for a
standardized unit is the quality adjusted life year (QALY), which equals the number of extra
years of life, or in the typical case for orthopaedics, extra years of function, multiplied by the
utility of those years for the patient. While utility assessment can be difficult, there are methods
for its calculation. One example is the Rosser Index Matrix, which determines patient utility on a
scale of 0 to 1 by comparing disability ratings of orthopaedics patients to the self-reported distress
of the patient [106]. Once these standardized utilities are obtained, a cost utility analysis can be
performed, as was done in the articles here.

Nonetheless, convention favors the use of cost effectiveness to mean cost utility. For the sake of
ease, I follow this convention.
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Appendix B – Literature Review for Core Decompression
A.1. Summary of Literature Search

A.1.1 Search Strategy
Keywords (in permutation)

Osteonecrosis, decompression, hip, outcome

Dates

1978-2004

Total articles

269

Articles not relevant

191

Relevant articles analyzed

78

Excluded reviews

15

Excluded articles <50 subjects

30

Excluded articles that failed criteria

22

Articles remaining from 78

11

A.1.2. Randomized Control Trial Used for Core Decompression and Conservative Treatment
A.1.2.1. Randomized control trial, more than 50 subjects

• Ref [30]
A.1.3. Articles Used for Core Decompression
A.1.3.1. Prospective, more than 50 subjects

• Refs [22, 24-26, 28, 29].
A.1.3.2. Retrospective, more than 50 subjects
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• Refs [23, 27].
A.1.4. Articles Used for Conservative Treatment

• Refs [20, 21].
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